Get started
Author

Ignacio Casarini

Observed names: I. Casarini, I.A. Casarini, Ignacio A. Casarini, Ignacio Alfredo Casarini
Observed institutions: Shanghai Jiao Tong University, National University of Mar del Plata, Sichuan University, Shanghai Chest Hospital, Instituto de Oncología de Rosario, University of Chinese Academy of Sciences, Huazhong University of Science and Technology
ORCID: 0000-0002-0479-9417
Observed ORCID: 0000-0002-0479-9417
OpenAlex ID: A5018480957
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,484
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
2020 · Jonathan W Goldman, Mikhail Dvorkin, et al. · The Lancet Oncology · 762
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
2024 · Shun Lu, Terufumi Kato, et al. · New England Journal of Medicine · 401
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
2024 · Christian Marth, Richard G. Moore, et al. · Journal of Clinical Oncology · 83
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress
2021 · Shun Lu, Ignacio Casarini, et al. · Clinical Lung Cancer · 68
Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial
2025 · E. Felip, C.I. Rojas, et al. · Annals of Oncology · 53
PDF
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study
2025 · Roy S. Herbst, Byoung Chul Cho, et al. · Journal of Thoracic Oncology · 22
PDF
Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
2023 · Terufumi Kato, Ignacio Casarini, et al. · Lung Cancer · 21
Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.
2024 · Suresh S. Ramalingam, Terufumi Kato, et al. · Journal of Clinical Oncology · 15
PDF
121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy
2023 · N. Peled, J. Mazieres, et al. · Immuno-Oncology Technology · 15
LBA4: Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): Updated overall survival (OS) analysis from the LAURA study
2025 · S.S. Ramalingam, M. Ozguroglu, et al. · Journal of Thoracic Oncology · 12
PDF
1463 Coformulated vibostolimab/pembrolizumab plus chemotherapy as first-line therapy vs atezolizumab plus chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC): randomized, phase 3 KEYVIBE-008
2024 · Jacob Sands, Shun Lu, et al. · Journal for ImmunoTherapy of Cancer · 6
64O Lenvatinib plus pembrolizumab, pemetrexed, and a platinum (len + pembro + chemo) as first-line therapy for metastatic non squamous non-small cell lung cancer (NSCLC): Phase III LEAP-006 study
2023 · R.S. Herbst, B.C. Cho, et al. · Immuno-Oncology Technology · 4
PDF
374TiP LAURA: Osimertinib maintenance following definitive chemoradiation therapy (CRT) in patients (pts) with unresectable stage III epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC)
2020 · S. Lu, I. Casarini, et al. · Annals of Oncology · 3
TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase 3, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical cancer.
2026 · Brian M. Slomovitz, Bradley J. Monk, et al. · Journal of Clinical Oncology · 2
PDF
Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer
2026 · Jacob Sands, Shun Lu, et al. · Targeted Oncology · 1
PDF
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy
2026 · Edurne Arriola, Ignacio Casarini, et al. · European Journal of Cancer · 1
From Res Cogitans to Digital Twins: Large Language Models, Large World Models, and the Illusion of Consciousness in the Brazilian Jiu-Jitsu Singularity
2026 · Enrique Díaz Cantón, Ignacio Casarini, et al. · Iberoamerican Journal of Medicine · 1
PDF
508 Biomarker analysis of coformulation of vibostolimab with pembrolizumab (vibo/pembro) with or without docetaxel for metastatic non-small-cell lung cancer (mNSCLC) after chemotherapy and immunotherapy
2025 · Maximilian J Hochmair, Julien Mazieres, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
A Podcast on Osimertinib After CRT in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): Current and Future Perspectives
2026 · Thanyanan Reungwetwattana, Kristin A. Higgins, et al. · Targeted Oncology
PDF
Trofuse-036/gog-3123/engot-cx22: a 2-part, Phase 3, Randomized Study of First-line Maintenance Sacituzumab Tirumotecan + Pembrolizumab ± Bevacizumab Vs Standard of Care for Pd-l1–positive Cervical Cancer
2026 · Brian M. Slomovitz, Bradley Monk, et al. · International Journal of Gynecological Cancer
Osimertinib after Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and Post-progression Outcomes from the Phase III LAURA Study
2026 · Mustafa Özgüroğlu, Myung-Ju Ahn, et al. · Clinical Cancer Research
PDF
48TiP TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical cancer
2026 · B.M. Slomovitz, B.J. Monk, et al. · ESMO Open
PDF
149 A Phase 2 Study of Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously
2026 · I. Casarini, A. Sumbul, et al. · Journal of the American Pharmacists Association
Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study
2026 · Ignacio A. Casarini, Dariusz M. Kowalski, et al. · JCO Oncology Practice
PDF
Works count: 34
Citation count: 3,955
H-index: 11
I10-index: 11
Year
Topic
Type